RCS - Tristel PLC - Tristel™ ULT case study

TristelAnnouncement

08/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240508:nRSH5062Na&default-theme=true

RNS Number : 5062N  Tristel PLC  08 May 2024

TRISTEL plc

("Tristel", the "Company", or the "Group")

 

Tristel™ ULT case study

 

Tristel ULT highlighted as novel method to simplify high-level disinfection
for urological procedures

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products
utilising proprietary chlorine dioxide technology, welcomes the publication of
a white paper "Simplifying High-Level Disinfection for Urological Procedures:
A Case Study" at the American Urological Association ("AUA") 2024 conference,
the largest gathering of urologists in the world. In the paper, US urologist,
Dr Matthew Allaway, highlights Tristel™ ULT in a case study, commenting on
the product's ability to enable faster, simpler endocavitary probe processing
for busy urology practices.

 

 

 

The paper which was released on 4 May 2024, highlights Tristel™ ULT as an
alternative to conventional chemical soaking and misting products. In June
2023 the Food and Drug Administration ("FDA") created a new category of Class
II medical device disinfectants titled "foam or gel chemical
sterilant/high-level disinfectant" under which De Novo clearance for
Tristel™ ULT was granted.

 

As referenced within Dr Allaway's study, Tristel™ ULT is recognised as a
high level disinfectant ("HLD") and is effective against pathogens ranging
from Human papillomavirus ("HPV") type 16 and type 18 to Mycobacterium terrae.
Tristel™ ULT helps to address numerous bottlenecks that can impact workflow
in a busy urology practice. One of the most time-consuming tasks is
reprocessing medical devices between procedures. Chemical soaking and misting
methods of HLD can damage probes and require complex workflows limiting the
number of procedures clinicians can perform during a typical patient list. As
the paper highlights:

 

"Unlike conventional germicidal agents, HLD with Tristel ULT does not require
specialized equipment, plumbing, or electricity and can be performed at the
point of use. Its substantially faster reprocessing time allows for high
throughput-more procedures can be performed in less time compared to
conventional disinfection methods."

 

Paul Swinney, CEO of Tristel, commented: "Our commercial partner, Parker
Laboratories Inc., is presenting Tristel™ ULT alongside its range of
ultrasonic gels and probe covers at multiple healthcare conferences this year.
The most notable is the forthcoming American Prevention of Infection Congress
("APIC") in Texas in June. We first announced our FDA approval at this same
event held in Orlando last year. In our first 12 months in the United States
market, brand recognition of Tristel™ ULT has grown rapidly, and this case
study will accelerate our progress further."

 

For further information please contact:

 

 Tristel plc                                      Tel: 01638 721 500
 Paul Swinney, Chief Executive Officer            www.investors.tristel.com (http://www.investors.tristel.com/)
 Liz Dixon, Chief Financial Officer

 Walbrook PR Ltd                                  Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus                                     Mob: 07980 541 893
 Alice Woodings                                   Mob: 07407 804 654

 Cavendish Capital Markets Ltd                    Tel: 020 7220 0500
 Geoff Nash / Charlie Beeson (Corporate Finance)
 Sunila de Silva (ECM)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, in a format which is a sustainable alternative to
commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 250 people across 14
subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKDLFBZELBBBL